You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Grifols’ Tavlesse receives NICE recommendation

Grifols has announced that its treatment for adults with chronic immune thrombocytopenia (ITP), Tavlesse – also known as fostamatinib – is now recommended by the National Institute for Health and Care Excellence (NICE).